Novo Nordisk A/S (NYSE:NVO) Position Trimmed by Shikiar Asset Management Inc.

Shikiar Asset Management Inc. trimmed its stake in Novo Nordisk A/S (NYSE:NVO - Free Report) by 13.6% in the fourth quarter, according to the company in its most recent disclosure with the SEC. The firm owned 96,159 shares of the company's stock after selling 15,085 shares during the quarter. Novo Nordisk A/S comprises 2.2% of Shikiar Asset Management Inc.'s portfolio, making the stock its 16th largest position. Shikiar Asset Management Inc.'s holdings in Novo Nordisk A/S were worth $8,272,000 as of its most recent filing with the SEC.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of NVO. International Assets Investment Management LLC lifted its position in Novo Nordisk A/S by 10,608.4% during the third quarter. International Assets Investment Management LLC now owns 1,813,571 shares of the company's stock valued at $215,942,000 after buying an additional 1,796,635 shares in the last quarter. DSM Capital Partners LLC lifted its position in Novo Nordisk A/S by 257,816.0% during the second quarter. DSM Capital Partners LLC now owns 1,593,921 shares of the company's stock valued at $227,516,000 after buying an additional 1,593,303 shares in the last quarter. Mediolanum International Funds Ltd acquired a new position in shares of Novo Nordisk A/S during the third quarter worth $98,765,000. Marshall Wace LLP lifted its position in shares of Novo Nordisk A/S by 34,472.1% during the second quarter. Marshall Wace LLP now owns 691,441 shares of the company's stock worth $98,696,000 after purchasing an additional 689,441 shares in the last quarter. Finally, Wellington Management Group LLP acquired a new position in shares of Novo Nordisk A/S during the third quarter worth $42,017,000. 11.54% of the stock is owned by institutional investors and hedge funds.

Novo Nordisk A/S Stock Down 5.2 %

Shares of NYSE:NVO traded down $4.33 during midday trading on Friday, reaching $78.74. The company had a trading volume of 21,239,835 shares, compared to its average volume of 8,206,201. The company has a debt-to-equity ratio of 0.43, a current ratio of 0.94 and a quick ratio of 0.75. The stock's fifty day moving average price is $98.33 and its 200-day moving average price is $117.69. The stock has a market capitalization of $353.33 billion, a P/E ratio of 25.48, a PEG ratio of 0.92 and a beta of 0.45. Novo Nordisk A/S has a one year low of $78.17 and a one year high of $148.15.

Analysts Set New Price Targets

NVO has been the topic of a number of recent research reports. StockNews.com cut shares of Novo Nordisk A/S from a "strong-buy" rating to a "buy" rating in a research report on Sunday, December 29th. Cantor Fitzgerald reissued an "overweight" rating and set a $160.00 target price on shares of Novo Nordisk A/S in a research report on Wednesday, November 6th. BNP Paribas raised shares of Novo Nordisk A/S to a "strong-buy" rating in a research report on Monday, December 2nd. UBS Group raised shares of Novo Nordisk A/S from a "sell" rating to a "buy" rating in a research report on Wednesday, January 8th. Finally, BMO Capital Markets reduced their target price on shares of Novo Nordisk A/S from $156.00 to $105.00 and set an "outperform" rating on the stock in a research report on Monday, December 23rd. One equities research analyst has rated the stock with a hold rating, seven have given a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, Novo Nordisk A/S presently has an average rating of "Buy" and a consensus target price of $140.20.

About Novo Nordisk A/S

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.